127294-73-9

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-Aminopiperidine is used as a building block for the synthesis of various pharmaceutical compounds, given its ability to interact with biological molecules. This interaction allows it to be incorporated into drug structures that can target specific biological processes or receptors, making it a valuable asset in the development of new medications.
Used in Drug Development:
(R)-3-Aminopiperidine is used as a key intermediate in the development of new drugs, particularly in the synthesis of chiral compounds. Its presence in the molecular structure can influence the drug's efficacy, selectivity, and potential side effects, making it a crucial component in the design and optimization of pharmaceutical agents.
Used in Research and Development:
(R)-3-Aminopiperidine is used as a research tool in the study of biological processes and the development of new therapeutic strategies. Its unique properties and interactions with biological molecules make it an important compound for understanding the mechanisms of action of various drugs and for identifying potential new drug targets.
Used in Chiral Synthesis:
(R)-3-Aminopiperidine is used as a chiral auxiliary in the synthesis of enantiomerically pure compounds. Its presence can help control the stereochemistry of a reaction, leading to the formation of a single enantiomer, which is particularly important in the pharmaceutical industry where the desired biological activity is often associated with a specific enantiomer.

InChI:InChI=1/C5H12N2/c6-5-2-1-3-7-4-5/h5,7H,1-4,6H2/t5-/m1/s1

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 4318-76-7 pyridine-2,5-diamine 
• 64-17-5 ethanol 
• 2530-26-9 3-nitropyridine 
• 42538-31-8 (3S)-3-aminopiperidin-2-one hydrochloride 
• 34294-79-6 (S)-(-)-3-aminopiperidin-2-one 
• 16682-12-5 D-ornithine hydrochloride 
• 40216-82-8 methyl (S)-2,5-diaminopentanoate dihydrochloride 
• 94695-52-0 1-cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydroquinolin-3-carboxylic acid 
• 54012-73-6 3-aminopiperidine 
• 3184-13-2 L-ornithine hydrochloride 

Downstream Products

• 144243-24-3 tert‐butyl 3‐aminopiperidine‐1‐carboxylate 
• 184637-48-7 t-butyl piperidin-3-ylcarbamate 
• 62813-09-6 3-(phthalimido)piperidine 
• 1352756-66-1 (R)-piperidine-3-amine dibenzoyl-D-tartrate 
• 54012-73-6 (S)-piperidin-3-amine 
• 1247828-69-8 C₁₁H₁₅N₃O₂ 
• 334618-23-4 3-(R)-aminopiperidine dihydrochloride 
• 334618-23-4 (S)-(-)-3-aminopiperidine dihydrochloride 
• 1029644-06-1 1-[2-(4-fluorophenyl)ethyl]piperidine-3-amine 

Relevant academic research and scientific papers

Reactions of Copper(II) Complexes of Optically Active N-Substituted Diamines with Alk-3-en-2-ones or 4-Hydroxyalkan-2-ones: Formation of Optically Active Macrocycles

The reaction of biscopper(II) with but-3-en-2-one in methanol in the presence of ammonia gives an optically active tetra-azamacrocyclic comlex in ca. 80percent yield.Analogous optically active complexes are also obtained from biscopper(II) or biscopper(II) by the same procedure.The introduction of methyl and/or a hydroxyl group at the C4 position of but-3-en-2-one leads to a decrease in the reactivity of the ketones, and changes the species and distribution of the reaction products.In particular, when the C4 position is fully substituted with methyl groups, C-N bond formation with the secondary amino group no longer proceeds.The change in the reaction mode due to the substituents at C4 is discussed.

Dielectrically controlled resolution (DCR) of 3-aminopiperidine via diastereomeric salt formation with N-tosyl-(S)-phenylalanine

A useful key intermediate for the dipeptidyl peptidase-4 (DPP-4) inhibitor, 3-aminopiperidine 1, was successfully resolved with an enantiomerically pure resolving agent, N-tosyl-(S)-phenylalanine 2, to give both stereoisomers (R)-1 and (S)-1 as a less-sol

One-pot synthesis of cyclohexylamine and: N -aryl pyrroles via hydrogenation of nitroarenes over the Pd0.5Ru0.5-PVP catalyst

The direct synthesis of cyclohexylamine via the hydrogenation of nitrobenzene over monometallic (Pd, Ru or Rh) and bimetallic (PdxRu1-x) catalysts was studied. The Pd0.5Ru0.5-PVP catalyst was the most effective catalyst for this reaction. The catalyst can be reused and applied for the synthesis of N-aryl pyrroles and quinoxalines from nitrobenzenes.

Substituted xanthine compound and its preparation and use (by machine translation)

The invention discloses substituted xanthine compounds, a preparation method and applications thereof, and specifically relates to compounds represented by the formula (I), stereo isomers and pharmaceutically acceptable salts thereof, wherein the R1 and R2 are defined in the description. The invention also relates to a pharmaceutical composition containing the compounds, an application of the pharmaceutical composition in preparation of drugs for treating diseases or symptoms caused by high activity of DPP-IV or overexpression of DPP-IV, and a method using the pharmaceutical composition to treat related diseases. The provided compounds can effectively inhibit the activity of DPP-IV.

Novel chiral derivatizing agents for 1H NMR determination of enantiomeric purities of carboxylic acids

(S)-4-(3-Aminopyrrolidin-1-yl)coumarin (1), (S)-4-(3-aminopiperidin-1-yl)coumarin (4), and (S)-4-(3-aminoazepan-1-yl)coumarin (7), prepared from 4-chlorocoumarin and (S)-pyrrolidin-3-amine, (S)-piperidin-3-amine, and (S)-azepan-3-amine, respectively, were proven to be versatile and reliable 1H NMR optical purity determination agents for chiral carboxylic acids.

A protection strategy substantially enhances rate and enantioselectivity in ω-transaminase-catalyzed kinetic resolutions

The kinetic resolution of 3-aminopyrrolidine (3AP) and 3-aminopiperidine (3APi) with ω-transaminases was facilitated by the application of a protecting group concept. 1-N-Cbz-protected 3-aminopyrrolidine could be resolved with >99% ee at 50% conversion, the resolution of 1-N-Boc-3-aminopiperidine yielded 96% ee at 55% conversion. The reaction rate was up to 50-fold higher by using protected substrates. Most importantly, enantioselectivity increased remarkably after carbamate protection compared to the unprotected substrates (86 vs. 99% ee). Surprisingly, benzyl protection of 3AP had no influence on enantioselectivity. A possible explanation for this observation could be the different flexibility of the benzyl- or carbamate-protected 3AP as confirmed by NMR spectroscopy.

8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS

The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof.

METHOD FOR PRODUCING 3-AMINOPIPERIDINE DIASTEREOMER

A method for increasing the enantiomeric purity of a desired enantiomer of 3- aminopiperidine comprising: providing a composition containing (i?)-3-arninopiperidine and (jS)-3-aminopiperidine; combining the composition with a resolving agent selected from

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part III: Synthesis of potent antagonists with αvβ3/α IIbβ3 dual activity and improved water solubility

In order to optimize our novel integrin αvβ 3/αIIbβ3 dual antagonists, spatial screening at the N-terminus was performed. The αvβ 3 antagonistic activity varied depending on the space that was occupied by the N-terminus, but high potency against αIIbβ 3 was well maintained. The (3S)-aminopiperidine analogue had the strongest activity against αvβ3, and the S isomer at piperidine was more potent than the R isomer. Compounds selected on the basis of SAR analysis of a novel lead compound showed acceptable early absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles and sufficient water solubility for use as infusion drugs. Docking studies with the αvβ3 receptor were performed to confirm the SAR findings.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part IV: Preliminary control of αvβ3 selectivity by meta-oriented substitution

To establish the in vivo efficacy of αvβ3/αIIbβ3 dual antagonists possessing a tricyclic pharmacophore, a corresponding αvβ3-selective antagonist was required as a control. We initially too